Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Cleveland Clinic Lerner College of Medicine, Université Paris-Saclay, Institut Gustave Roussy, National and Kapodistrian University of Athens, The Maria Sklodowska-Curie National Research Institute of Oncology, The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, Merck & Co., Inc., Rahway, NJ, USA (United States), Amgen (United States), University of Louisville
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281657020